Anavex Life Sciences Corp (AVXL)

[falconer66a]

Diligent academic publication caution.

In the press release, Anavex states:

A significant reduction in pathological amyloid beta levels in plasma1,...

Ok, then, why didn't they tell the metrics, the actual numbers of this reduction?

To me, pretty clear. Those are being retained and embargoed until they appear in a peer-reviewed medical journal article. Scientific journals are very defensive in what they allow authors to announce before a research paper is formally published in the specific journal. All along, Missling and company have told only the fragments of what they know, so as not to endanger their abilities to get a data-filled research paper published in a top-line, peer-reviewed medical journal.

When that article appears, in JAMA (Journal of the American Medical Association), NEJM (New England Journal of Medicine), The Lancet, or any neurology journal, the New York Times will have to write a story on it. They will tell that "Results are promising, but further studies will surely be needed."

Sure. But the blarcamesine horse will then be out of the barn, prancing about in front of Alzheimer's support groups. Everything about Alzheimer's therapy will then change.